444 Impact of homologous recombination deficiency on response to chemoimmunotherapy in biliary tract cancer
Oluseyi Abidoye(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Taro Shibuki(National Cancer Center Hospital East), Mitesh J. Borad(Jacksonville College), Masafumi Ikeda(National Cancer Center Hospital East), Chigusa Morizane, Naohiro Okano(Kyorin University), Heidi Kosiorek(Mayo Clinic in Florida), Mitsuho Imai-Sumida(University of California, San Francisco), Manuel Teixeira(Hospital Israelita Albert Einstein), Takao Fujisawa(National Cancer Center Hospital East), Hideaki Bando(National Cancer Center Hospital East), Mohamad Bassam Sonbol(WinnMed), Takayuki Yoshino(University of Tsukuba), Daniel H. Ahn(Mayo Clinic Hospital), Angelo Pirozzi, Celine Hoyek(Mayo Clinic Hospital), Christina Wu(WinnMed), John H. Strickler(Duke Medical Center), Pedro LS(Hospital Israelita Albert Einstein), Yoshiaki Nakamura(National Cancer Center Hospital East)
Cited by 0
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k